Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

Pfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its first quarter on the market and looks set to quickly enter blockbuster territory.

Pfizer’s Vyndaqel has become the first drug to be approved for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in Europe, adding further momentum to the fast-growing product. Vyndaqel ...

Please watch the video at Investors.com - These Three Factors Will Drive Medical Stocks In 2025 Alnylam Pharmaceuticals will take on Pfizer's Vyndaqel and BridgeBio Pharma's new Attruby.

Use code FY25SAVE at checkout. What does the future hold for the Vyndaqel market in terms of growth and opportunities? The Vyndaqel market has seen remarkable growth in recent years. Its value is ...

This growth was fueled by a one-time, non-cash revenue reversal associated with its COVID-19 antiviral, Paxlovid, as well as ...

Listed below are the charts and positions for Vyndaqel/Vyndamax in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Vyndaqel/Vyndamax. GlobalData provides trusted ...

It loses patent exclusivity in the U.S. in 2027. The company's fourth-highest moneymaker in its Vyndaqel franchise, which raked in close to $5.5 billion in 2024. Vyndaqel's key U.S. patent is ...

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

Prevnar 13 is expected to lose patent-protected exclusivity in the U.S. next year. Vyndaqel has been a strong growth driver for Pfizer but probably not for much longer. This treatment prevents ...